Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea

Molecular Characteristics and Prevalence of Rifampin Resistance in Staphylococcus aureus Isolates from Patients with Bacteremia in South Korea

“…The amino acid substitution A477D was the most prevalent in our study, which was inconsistent with findings reported from previous studies that showed the H481Y MRSA clone was predominant [8,9,13,31]. Furthermore, the transformation of A477Dmutated rpoB into wild-type S. aureus strains resulted in a RIF-R phenotype, indicating that these mutations contribute to rifampicin resistance in S. aureus.…”

“…A key strength of our study was the evaluation of a large number of S. aureus blood isolates (n = 1615); ST5-SCCmecII (543/1615, 33.6%) and ST72-SCCmecIV (403/1615, 25.0%) were the major clones in South Korea, which reinforced the results of previous molecular epidemiology studies. To the best of our knowledge, this is the first study to evaluate the molecular characteristics of RIF-R S. aureus blood isolates in South Korea, and we identified molecular characteristics distinct from those reported in previous studies on RIF-R S. aureus clinical isolates [8,9,13,23].…”

“…However, in South Korea, an accurate understanding of these characteristics is lacking, as there is limited information on the molecular characteristics of RIP-R and rpoB mutations in S. aureus infections. A recent study identified rifamycin resistance and rpoB gene mutations in Staphylococcus species isolates from prosthetic joint infections [13]; nonetheless, there is a paucity of data on the molecular epidemiology and prevalence of RIF-R and rpoB mutations in S. aureus isolates from patients with bacteremia in South Korea. With regard to treatment and infection control, the dissemination of RIF-R isolates in S. aureus bacteremia may pose a serious threat, and this highlights the importance of understanding the molecular epidemiology of S. aureus isolates.…”

Tuning the Drug Release from Antibacterial Polycaprolactone/Rifampicin-Based Core–Shell Electrospun Membranes: A Proof of Concept

“…When considering biomaterials for tissue regeneration, the risk of infections represents the most serious complication hindering the structural and functional recovery of the disrupted tissue. − For this reason, functionalization with antibacterial compounds, such as antibiotics or antimicrobial peptides, could be crucial in guaranteeing the restoration of the injured site. − Among them, rifampicin is one of the most effective broad-spectrum bactericidal antibiotics, which blocks the RNA-polymerase β subunit, inhibiting the transcription and subsequent bacterial protein synthesis. , It demonstrated its activity against both Gram-positive and Gram-negative bacteria, being particularly effective in the case of biofilm formation by staphylococci. − Several polymers, such as poly­(lactic acid), poly­(vinyl alcohol), or poly­(lactic acid-co-glycolic acid) have already been studied to produce rifampicin-based antibacterial nanofibrous structures. − Among them, even rifampicin-loaded PCL membranes for orthopedic application have been characterized, revealing their antibacterial effect against Pseudomonas aeruginosa and Staphylococcus epidermis in the first 6 h …”

“… 58 − 61 Among them, rifampicin is one of the most effective broad-spectrum bactericidal antibiotics, which blocks the RNA-polymerase β subunit, inhibiting the transcription and subsequent bacterial protein synthesis. 62 , 63 It demonstrated its activity against both Gram-positive and Gram-negative bacteria, being particularly effective in the case of biofilm formation by staphylococci. 64 − 66 Several polymers, such as poly(lactic acid), poly(vinyl alcohol), or poly(lactic acid-co-glycolic acid) have already been studied to produce rifampicin-based antibacterial nanofibrous structures.…”